KV Pharmaceutical e-mail alert overstated drug efficacy

Share this article:
The FDA says a KV Pharmaceutical e-mail alert announcing the availability of Clindesse on a formulary overstated and misrepresented the efficacy of the drug, which is indicated for treating bacterial vaginosis. The FDA says the e-mail presents unsubstantiated superiority and patient compliance claims, and minimizes the risks and limitations.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.